Literature DB >> 2471770

Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma.

B Mukherji1, A Guha, N G Chakraborty, M Sivanandham, A L Nashed, J R Sporn, M T Ergin.   

Abstract

T cell-mediated immune response against autologous melanoma cells was analyzed, at population and clonal levels, in 31 patients with recurrent and/or metastatic disease. Fresh PBL and lymph node lymphocytes (LNL) from melanoma-involved nodes were not cytotoxic against the respective melanoma cells. When activated in in vitro coculture (IVC) against the autologous melanoma cells in the presence of IL-2, a majority of the activated PBL and LNL became cytotoxic against the autologous targets. The activated effector cells were cloned in limiting dilution microcultures, and growing clones were phenotypically defined and were functionally characterized for cytotoxicity and for potential regulatory function. Functional T cell clones were obtained from 15 of 31 cases. Of these, CTL responses exhibiting cytotoxicity restricted against the autologous melanoma were seen in four cases. All four CTL clones were CD3+, CD8+, and CD4-. Three of these four CTL clones were studied extensively. All three of these CTL clones expressed MHC class I-restricted cytotoxicity. mAb anti-CD3 blocked cytotoxicity in two and enhanced cytotoxicity in the other. Neither autologous sera nor autologous nonactivated fresh PBL modulated the cytotoxic functions of the CTL clones at the effector phase. T cell lines exhibiting regulatory function were obtained in 11 cases. The regulatory T cell lines were CD3+, CD4+, and CD8-. In three cases CD4+ clones amplified the cytotoxic response in the PBL in coculture, while in eight other cases the T cell lines downregulated the cytotoxic responses. Such T cell-mediated down-regulations were either restricted to the autologous system, induced by D/DR antigens expressed by the autologous or allogeneic melanoma cells, or induced by stimulus other than D/DR antigens. Taken together, these findings clearly demonstrate the existence of T cell-mediated cytotoxic and regulatory responses against human melanoma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2471770      PMCID: PMC2189343          DOI: 10.1084/jem.169.6.1961

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  31 in total

1.  Regualtion of the immune response to tumor antigens. I. Immunosuppressor cells in tumor-bearing hosts.

Authors:  S Fujimoto; M I Greene; A H Sehon
Journal:  J Immunol       Date:  1976-03       Impact factor: 5.422

2.  Specificity and suppressor function of human T cells responsive to autologous non-T cells.

Authors:  T Sakane; I Green
Journal:  J Immunol       Date:  1979-08       Impact factor: 5.422

3.  Cellular interaction between cytotoxic and suppressor T cells against syngeneic tumors in the mouse.

Authors:  S Fujimoto; T Matsuzawa; K Nakagawa; T Tada
Journal:  Cell Immunol       Date:  1978-07       Impact factor: 4.868

Review 4.  Suppressor cells: permitters and promoters of malignancy?

Authors:  D Naor
Journal:  Adv Cancer Res       Date:  1979       Impact factor: 6.242

5.  Lack of suppressive activity of human primary melanoma cells on the activation of autologous lymphocytes.

Authors:  D Taramelli; A Mazzocchi; C Clemente; G Fossati; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

6.  Immune response to a syngeneic mammary adenocarcinoma. III. Development of memory and suppressor functions modulating cellular cytotoxicity.

Authors:  O Kuperman; G W Fortner; Z J Lucas
Journal:  J Immunol       Date:  1975-11       Impact factor: 5.422

7.  In vitro induction of cytotoxicity against syngeneic mastocytoma and its suppression by spleen and thymus cells from tumor-bearing mice.

Authors:  F Takei; J G Levy; D G Kilburn
Journal:  J Immunol       Date:  1976-02       Impact factor: 5.422

8.  Expression of Ia-like antigens on cultured human malignant melanoma cell lines.

Authors:  R J Winchester; C Y Wang; A Gibofsky; H G Kunkel; K O Lloyd; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1978-12       Impact factor: 11.205

9.  T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor.

Authors:  M J Berendt; R J North
Journal:  J Exp Med       Date:  1980-01-01       Impact factor: 14.307

10.  Signal transduction through the EGF receptor transfected in IL-3-dependent hematopoietic cells.

Authors:  J H Pierce; M Ruggiero; T P Fleming; P P Di Fiore; J S Greenberger; L Varticovski; J Schlessinger; G Rovera; S A Aaronson
Journal:  Science       Date:  1988-02-05       Impact factor: 47.728

View more
  35 in total

1.  Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination.

Authors:  Matteo Vergati; Vittore Cereda; Ravi A Madan; James L Gulley; Ngar-Yee Huen; Connie J Rogers; Kenneth W Hance; Philip M Arlen; Jeffrey Schlom; Kwong Y Tsang
Journal:  Cancer Immunol Immunother       Date:  2010-10-26       Impact factor: 6.968

2.  Growth stimulation of tumor-specific cytotoxic T lymphocytes on concanavalin a-immobilized carrier beads.

Authors:  S Q Liu; L S Liu; T Ohno
Journal:  Cytotechnology       Date:  1998-01       Impact factor: 2.058

3.  Induction of auto-logous human cytotoxic T lymphocytes (CTL) from peripheral blood against tumor cells.

Authors:  T Ohno
Journal:  Cytotechnology       Date:  1997-01       Impact factor: 2.058

4.  Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepatocellular carcinoma growth in vitro and in vivo.

Authors:  Yang Liu; Lisa H Butterfield; Xiaohui Fu; Zhenshun Song; Xiaoping Zhang; Chongde Lu; Guanghui Ding; Mengchao Wu
Journal:  Int J Oncol       Date:  2011-04-13       Impact factor: 5.650

5.  Analysis of circulating regulatory T cells (CD4+CD25+CD127-) after cryosurgery in prostate cancer.

Authors:  Tong-Guo Si; Jun-Ping Wang; Zhi Guo
Journal:  Asian J Androl       Date:  2013-06-03       Impact factor: 3.285

6.  In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites.

Authors:  M Hishii; D Andrews; L A Boyle; J T Wong; F Pandolfi; P J van den Elsen; J T Kurnick
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

7.  The expression and cellular distribution of adhesion molecules CD2/LFA-3 and ICAM-1/LFA-1 on mononuclear cells in squamous cell carcinoma of the head and neck.

Authors:  J Kornfehl; C Neuchrist; M C Grasl; K Ehrenberger; D Kraft; O Scheiner
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

8.  Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells.

Authors:  B Mukherji; N G Chakraborty; S Yamasaki; T Okino; H Yamase; J R Sporn; S K Kurtzman; M T Ergin; J Ozols; J Meehan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

9.  T cell recognition of melanoma antigens in association with HLA-A1 on allogeneic melanoma cells.

Authors:  Q Chen; M Smith; T Nguyen; D W Maher; P Hersey
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

10.  IFN-γ upregulates survivin and Ifi202 expression to induce survival and proliferation of tumor-specific T cells.

Authors:  Mary Zimmerman; Dafeng Yang; Xiaolin Hu; Feiyan Liu; Nagendra Singh; Darren Browning; Vadivel Ganapathy; Phillip Chandler; Divaker Choubey; Scott I Abrams; Kebin Liu
Journal:  PLoS One       Date:  2010-11-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.